FIG 7.

Characterization of viruses harboring RGD sequence using cancer cell lines expressing low levels of JAM-A. (A and C) Transcription of JAM-A, ITGAV, ITGB3, and ITGB5 in cancer cell lines. mRNA was extracted from cells and levels were measured by quantitative reverse transcription-PCR (RT-qPCR). Each value represents an average from triplicate samples. The error bars indicate the standard deviation. Representative results from two independent experiments are shown. (B and D) Cell surface expression of JAM-A, integrin αVβ3, and integrin αVβ5 by cancer cell lines. Cancer cell lines were collected in a nonenzymatic solution and then stained with mouse antiserum against JAM-A (B) or with an anti-integrin αVβ3 (LM609) or an anti-integrin αVβ5 antibody (P1F6) (D), followed by an Alexa 488-conjugated secondary antibody. Cells were then subjected to flow cytometry analysis. (E) Human cancer cells were infected with each virus at an MOI of 10 PFU/cell. Cell viability was determined by propidium iodide staining. Each value represents an average from triplicate samples. The error bars indicate the standard deviation. Representative results from two independent experiments are shown. Significant differences were determined using one-way ANOVA; ***, P < 0.0001.